S
Stephanie Burnett
Researcher at Institute of Cancer Research
Publications - 12
Citations - 527
Stephanie Burnett is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Medicine & Randomized controlled trial. The author has an hindex of 5, co-authored 9 publications receiving 282 citations.
Papers
More filters
Journal ArticleDOI
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Douglas Brand,Douglas Brand,Alison Tree,Alison Tree,Peter Ostler,Hans van der Voet,Andrew Loblaw,William Chu,Daniel Ford,Shaun Tolan,Suneil Jain,Alexander G.R. Martin,John Staffurth,Philip Camilleri,Kiran Kancherla,John Frew,Andrew K Chan,Ian S. Dayes,Daniel Henderson,Stephanie Brown,Clare Cruickshank,Stephanie Burnett,A. Duffton,Clare Griffin,Victoria Hinder,Kirsty Morrison,Kirsty Morrison,O. Naismith,Emma Hall,Nicholas van As,Nicholas van As,D Dodds,E Lartigau,S Patton,Alan J. Thompson,Mathias Winkler,P Wells,T Lymberiou,Daniel Saunders,M Vilarino-Varela,P Vavassis,Theodoros Tsakiridis,R Carlson,George Rodrigues,Jacob Tanguay,S Iqbal,Scott C. Morgan,A Mihai,A Li,O Din,Miguel Panades,R Wade,Yvonne Rimmer,J Armstrong,N Oommen +54 more
TL;DR: The results suggest that substantially shortening treatment courses with stereotactic body radiotherapy does not increase either gastrointestinal or genitourinary acute toxicity.
Journal ArticleDOI
Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001)
S. Nicholson,Emma Hall,S. J. Harland,John D. Chester,John D. Chester,Lisa Pickering,Jim Barber,Tony Elliott,Alastair Thomson,Stephanie Burnett,Clare Cruickshank,Bernadette M Carrington,Rachel Waters,Amit Bahl +13 more
TL;DR: The results do not support the routine use of TPF, but the observed complete responses support further investigation of combination chemotherapy in the neoadjuvant setting.
Journal ArticleDOI
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Alison Tree,Peter Ostler,H. van der Voet,William C. Cho,Andrew Loblaw,Daniel Ford,Shaun Tolan,Suneil Jain,Alexander G.R. Martin,John Staffurth,John G. Armstrong,Philip Camilleri,Kiran Kancherla,John Frew,Andrew K Chan,Ian S. Dayes,A. Duffton,Douglas Brand,D. Henderson,Kirsty Morrison,Stephanie Brown,Julia Pugh,Stephanie Burnett,Muneeb Mahmud,Victoria Hinder,O. Naismith,Emma Hall,Nicholas van As +27 more
TL;DR: PACE-B as discussed by the authors , a randomized trial of conventional fractionated or moderately hypofractionated radiotherapy versus Stereotactic Body Radiotherapy (SBRT), was conducted at 35 hospitals in the UK, Ireland, and Canada.
Journal ArticleDOI
PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa).
Nicholas van As,Douglas Brand,Alison Tree,Peter Ostler,William Chu,Andrew Loblaw,Daniel Ford,Shaun Tolan,Suneil Jain,Alexander S. Martin,John Staffurth,Stephanie Brown,Stephanie Burnett,A. Duffton,Clare Griffin,Vicki Hinder,Kirsty Morrison,O. Naismith,Emma Hall +18 more
TL;DR: Key toxicity outcomes were worst grade 2+ Radiation Therapy Oncology Group (RTOG) genitourinary (GU) and gastrointestinal (GI) acute toxicities, compared by Chi-square test with alpha 0.05 divided between the two measures.
Journal ArticleDOI
BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)
John D. Kelly,Wei Shen Tan,Nuria Porta,Hugh Mostafid,Robert Huddart,Andrew Protheroe,Richard Bogle,Jane M Blazeby,Alison Palmer,Jo Cresswell,Mark Johnson,Richard J. Brough,Sanjeev Madaan,Stephen Andrews,Clare Cruickshank,Stephanie Burnett,Lauren Maynard,Emma Hall,Boxit Investigators +18 more
TL;DR: Celecoxib was not shown to reduce the risk of recurrence in intermediate- or high-risk non-muscle-invasive bladder cancer (NMIBC), although cele Coxib was associated with delayed time to recurrenceIn pT1 NMIBC patients.